Docosahexaenoic acid-enriched phosphatidylcholine(DHA-PC) is a new generation of omega-3 lipids,which contains an ester bond linking DHA at the sn-2position of phospholipid. DHA-PC has become the interestrecently as its better bioavailability and anti-oxidationcapacity. In this study, the anti-angiogenic effect of DHAPCwas evaluated. The capacities of proliferation, migration,tube formation of human umbilical vein endothelialcells were significantly declined after DHA-PC treatment. Furthermore, DHA-PC inhibited the neovascularization ofthe chick chorioallantoic membrane in vivo. Mechanismresults indicated that DHA-PC enhances the expression ofperoxisome proliferator-activated receptor c (PPARc) attranscriptional and translational level, subsequently downregulatesthe VEGFR2 expression and VEGFR2-mediateddownstream Ras/ERK pathway, resulting in significantreduction in proliferation and differentiation. Additionally,PPARc-specific antagonist GW9662 partly reversed theinhibition effects of DHA-PC on tube formation and neovascularization,suggesting that DHA-PC exerts anti-angiogenesiseffect through activating PPARc. Thesefindings indicated that DHA-PC has a great prospect ofanti-tumor angiogenesis therapy.